Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jason Porter, MD, highlights the implications of recent data to emerge following the use of EGFR TKIs in the adjuvant setting, the importance of the potential upcoming FDA approval of osimertinib with chemotherapy in EGFR-positive non–small cell lung cancer, and more.
Molly Mendenhall, BSN, RN, director of quality and compliance at Oncology Hematology Care, Inc (OHC), discussed a 1-year quality improvement project implemented by OHC to standardize comprehensive biomarker testing in patients with non–small cell lung cancer (NSCLC).
A PMA application seeking approval of TTFields to standard therapies in patients with non–small cell lung cancer has been accepted for filing by the FDA.
The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.
The European Commission has granted marketing authorization for subcutaneous atezolizumab co-formulated with Enhanze, a recombinant human hyaluronidase enzyme rHuPH20, for all approved indications of intravenous atezolizumab.